Fintel reports that on September 20, 2023, HC Wainwright & Co. reiterated coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a Buy recommendation.
Analyst Price Forecast Suggests 199.10% Upside
As of August 31, 2023, the average one-year price target for Marinus Pharmaceuticals is 21.01. The forecasts range from a low of 9.09 to a high of $33.60. The average price target represents an increase of 199.10% from its latest reported closing price of 7.02.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Marinus Pharmaceuticals is 30MM, an increase of 16.80%. The projected annual non-GAAP EPS is -2.98.
What is the Fund Sentiment?
There are 196 funds or institutions reporting positions in Marinus Pharmaceuticals. This is an increase of 69 owner(s) or 54.33% in the last quarter. Average portfolio weight of all funds dedicated to MRNS is 0.18%, a decrease of 6.94%. Total shares owned by institutions increased in the last three months by 10.74% to 49,875K shares. 
The put/call ratio of MRNS is 0.11, indicating a bullish outlook.
What are Other Shareholders Doing?
Suvretta Capital Management holds 4,058K shares representing 8.02% ownership of the company. In it's prior filing, the firm reported owning 4,831K shares, representing a decrease of 19.07%. The firm increased its portfolio allocation in MRNS by 67.31% over the last quarter.
ETAHX - Eventide Healthcare & Life Sciences Fund Shares holds 3,173K shares representing 6.27% ownership of the company. No change in the last quarter.
Eventide Asset Management holds 3,173K shares representing 6.27% ownership of the company. No change in the last quarter.
Avoro Capital Advisors holds 3,150K shares representing 6.22% ownership of the company. No change in the last quarter.
Adage Capital Partners Gp, L.l.c. holds 2,731K shares representing 5.40% ownership of the company. In it's prior filing, the firm reported owning 2,034K shares, representing an increase of 25.51%. The firm increased its portfolio allocation in MRNS by 104.68% over the last quarter.
Marinus Pharmaceuticals Background Information
(This description is provided by the company.)
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
